BioSpace News Archive

MannKind Corporation announced that it has entered into an agreement with Zealand Pharma A/S to acquire V-Go® for $10 million, with additional sales-based milestones plus the cost of certain inventory.

Albany NY, United States: The manufacturers and players operational within the global resectoscopes market offer various unique types of products, including bipolar resectoscopes as well as unipolar resectoscopes.

International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, provided a business update and financial results for the three months ended March 31, 2022.

Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, announced the close of a $70 million Series B financing.

Nutriband Inc. announced it has booked nearly a quarter of a million dollars in new in contract manufacturing orders through its wholly-owned subsidiary Pocono Pharma, extending its current run of record-breaking revenue.

Amryt announces that, following the CHMP positive opinion for Filsuvez® on April 22, 2022, the European Medicines Agency Contingent Value Rights issued to those Amryt shareholders and option holders who held Amryt shares or options prior to the acquisition of Aegerion Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C Wainwright Global Healthcare Investment Conference.

Oncorus, Inc. announced that President and Chief Executive Officer, Theodore Ashburn, M.D., Ph.D., will present an update on the Company’s progress at the H.C. Wainwright Global Investment Conference.

AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, today presents preclinical data on its investigational, one-time, adeno-associated virus (AAV) gene therapy, AVB-101 (AVB-PGRN), in an oral presentation at the American Society of Gene & Cell Therapy annual meeting (ASGCT 2022).

Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation’s (NASDAQ:ZSAN) proprietary microneedle patch system.